A fully independent clinical trial researchers thought might disprove a cardiac device made by Shockwave Medical, the company that Johnson & Johnson is buying for $13 billion, ended up providing some ...

ATLANTA, GA—An implantable coronary sinus reducer (CSR) in patients with refractory angina significantly reduces symptoms over 6 months of follow-up compared with a placebo procedure, a new study ...

ATLANTA, GA — Despite failing to increase perfusion as hypothesized, a coronary sinus reducer (CSR) in a sham-controlled randomized trial meaningfully reduced angina and improved quality of life in ...

Please provide your email address to receive an email when new articles are posted on . A coronary sinus reducer reduced the frequency of angina events for patients with significant CAD. However, the ...

ATLANTA -- For people with stable coronary artery disease and refractory angina, a coronary sinus reducer (CSR) implant showed a symptom alleviation benefit in the small placebo-controlled ...

A recent state-of-the-art review overlooks a “safe and effective” therapy for patients with stable angina and no good treatment options, according to several cardiologists. The coronary sinus reducer ...

People with chronic chest pain who received a coronary sinus reducer (CSR)—a stent thought to increase the amount of oxygen-rich blood flowing to the heart muscle—experienced significant reductions in ...

Johnson & Johnson said it plans to let Shockwave Medical keep its dedicated selling team, as the company has a variety of specialized cardiovascular devices coming down its pipeline. (Paul ...